Nicolas Hunzelmann1, Stephan Rosenkranz2,3, Michael Huntgeburth4, Johannes Kießling4, Gerrit Weimann5, Verena Wilberg6, Soundos Saleh5. 1. Department of Dermatology, University of Cologne, Cologne, Germany. 2. Clinic III for Internal Medicine, Department of Cardiology, Heart Center, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany. stephan.rosenkranz@uk-koeln.de. 3. Heart Center, Cologne Cardiovascular Research Center (CCRC), Cologne, Germany. stephan.rosenkranz@uk-koeln.de. 4. Clinic III for Internal Medicine, Department of Cardiology, Heart Center, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany. 5. Bayer AG, Berlin, Germany. 6. ClinStat GmbH, Cologne, Germany.
Abstract
BACKGROUND AND OBJECTIVE: Raynaud's phenomenon (RP) is characterized by transient digital ischemia and is commonly associated with connective tissue disease. Treatment remains unsatisfactory. Here we evaluate the efficacy, safety, and pharmacokinetics of a single dose of the soluble guanylate cyclase stimulator riociguat in RP. METHODS: DIGIT was a double-blind, randomized, placebo-controlled pilot study. Patients with primary or secondary RP were randomized to a single oral dose of riociguat 2 mg or placebo in a cross-over design (7 ± 3 days). Efficacy was assessed as placebo-corrected change in digital blood flow 2 h post-dose at room temperature (RT) or following cold exposure (CE), measured by laser-speckle contrast analysis. Patients were regarded as responders if placebo-corrected digital blood flow increased by ≥ 10% from baseline at RT or after CE. RESULTS: Of 20 eligible patients, 17 (85%) were female and mean [standard deviation (SD)] age was 52 (13.8) years. Placebo-corrected changes in digital blood flow were + 46% [90% confidence interval (CI) - 6 to + 98] at RT and - 9% (90% CI - 63 to + 44) after CE, with high inter-individual variability. Eight patients (40%) were responders at RT, and 12 (60%) after CE. Riociguat increased mean (SD) digital blood flow in responders at RT by + 136% (114) and in responders following CE by + 39% (53). Riociguat was well tolerated, with few adverse events. CONCLUSION: In this pilot study, single-dose riociguat was well tolerated in patients with RP and resulted in improved digital blood flow in some patient subsets, with high inter-individual variability. Long-term evaluation is warranted.
RCT Entities:
BACKGROUND AND OBJECTIVE:Raynaud's phenomenon (RP) is characterized by transient digital ischemia and is commonly associated with connective tissue disease. Treatment remains unsatisfactory. Here we evaluate the efficacy, safety, and pharmacokinetics of a single dose of the soluble guanylate cyclase stimulator riociguat in RP. METHODS:DIGIT was a double-blind, randomized, placebo-controlled pilot study. Patients with primary or secondary RP were randomized to a single oral dose of riociguat 2 mg or placebo in a cross-over design (7 ± 3 days). Efficacy was assessed as placebo-corrected change in digital blood flow 2 h post-dose at room temperature (RT) or following cold exposure (CE), measured by laser-speckle contrast analysis. Patients were regarded as responders if placebo-corrected digital blood flow increased by ≥ 10% from baseline at RT or after CE. RESULTS: Of 20 eligible patients, 17 (85%) were female and mean [standard deviation (SD)] age was 52 (13.8) years. Placebo-corrected changes in digital blood flow were + 46% [90% confidence interval (CI) - 6 to + 98] at RT and - 9% (90% CI - 63 to + 44) after CE, with high inter-individual variability. Eight patients (40%) were responders at RT, and 12 (60%) after CE. Riociguat increased mean (SD) digital blood flow in responders at RT by + 136% (114) and in responders following CE by + 39% (53). Riociguat was well tolerated, with few adverse events. CONCLUSION: In this pilot study, single-dose riociguat was well tolerated in patients with RP and resulted in improved digital blood flow in some patient subsets, with high inter-individual variability. Long-term evaluation is warranted.
Authors: Muriel Elhai; Christophe Meune; Marouane Boubaya; Jérôme Avouac; Eric Hachulla; Alexandra Balbir-Gurman; Gabriela Riemekasten; Paolo Airò; Beatriz Joven; Serena Vettori; Franco Cozzi; Susanne Ullman; László Czirják; Mohammed Tikly; Ulf Müller-Ladner; Paola Caramaschi; Oliver Distler; Florenzo Iannone; Lidia P Ananieva; Roger Hesselstrand; Radim Becvar; Armando Gabrielli; Nemanja Damjanov; Maria J Salvador; Valeria Riccieri; Carina Mihai; Gabriella Szücs; Ulrich A Walker; Nicolas Hunzelmann; Duska Martinovic; Vanessa Smith; Carolina de Souza Müller; Carlo Maurizio Montecucco; Daniela Opris; Francesca Ingegnoli; Panayiotis G Vlachoyiannopoulos; Bojana Stamenkovic; Edoardo Rosato; Stefan Heitmann; Jörg H W Distler; Thierry Zenone; Matthias Seidel; Alessandra Vacca; Ellen De Langhe; Srdan Novak; Maurizio Cutolo; Luc Mouthon; Jörg Henes; Carlo Chizzolini; Carlos Alberto von Mühlen; Kamal Solanki; Simona Rednic; Lisa Stamp; Branimir Anic; Vera Ortiz Santamaria; Maria De Santis; Sule Yavuz; Walter Alberto Sifuentes-Giraldo; Emmanuel Chatelus; Jiri Stork; Jacob van Laar; Esthela Loyo; Paloma García de la Peña Lefebvre; Kilian Eyerich; Vanesa Cosentino; Juan Jose Alegre-Sancho; Otylia Kowal-Bielecka; Grégoire Rey; Marco Matucci-Cerinic; Yannick Allanore Journal: Ann Rheum Dis Date: 2017-08-23 Impact factor: 19.103
Authors: Peter Klein-Weigel; Andreas Ruttloff; Dana König; Jessica Nielitz; Julia Steindl; Oliver Sander; Jutta G Richter Journal: Inn Med (Heidelb) Date: 2022-05-16
Authors: Dinesh Khanna; Yannick Allanore; Christopher P Denton; Masataka Kuwana; Marco Matucci-Cerinic; Janet E Pope; Tatsuya Atsumi; Radim Bečvář; László Czirják; Eric Hachulla; Tomonori Ishii; Osamu Ishikawa; Sindhu R Johnson; Ellen De Langhe; Chiara Stagnaro; Valeria Riccieri; Elena Schiopu; Richard M Silver; Vanessa Smith; Virginia Steen; Wendy Stevens; Gabriella Szücs; Marie-Elise Truchetet; Melanie Wosnitza; Kaisa Laapas; Janethe de Oliveira Pena; Zhen Yao; Frank Kramer; Oliver Distler Journal: Ann Rheum Dis Date: 2020-05 Impact factor: 27.973